Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Dilemmas and challenges in apolipoprotein L1 nephropathy research

Kruzel-Davila, Ettya,b; Skorecki, Karla,b

Current Opinion in Nephrology and Hypertension: January 2019 - Volume 28 - Issue 1 - p 77–86
doi: 10.1097/MNH.0000000000000462
SPECIAL COMMENTARIES

Purpose of review The purpose of this mini-review is to highlight some unresolved questions and controversies in the evolving story of apolipoprotein L1 (APOL1) nephropathy.

Recent findings We highlight studies that introduce complexity in unraveling the mechanisms whereby APOL1 risk variant alleles cause disease. These include studies which support a possible protective role for the APOL1 GO nonrisk ancestral allele, and studies which explore the initiating events that may trigger other downstream pathways mediating APOL1 cellular injury. We also review studies that reconcile the perplexing findings regarding APOL1 anionic or cationic conductance, and pH dependency, and also studies that attempt to characterize the 3-dimensional structure of APOL1 C-terminal in APOL1 variants, as well as that of the serum resistance-associated protein. We also attempt to convey new insights from in-vivo and in-vitro models, including studies that do not support the differential toxicity of APOL1 renal risk variants and recapitulate the clinical variability of individuals at genotypic risk.

Summary Along with major progress that had been achieved in the field of APOL1 nephropathy, controversies and enigmatic issues persist. It remains to be determined which of the pathways which have been demonstrated to mediate cell injury by ectopically expressed APOL1 risk variants in cellular and organismal models are relevant to human disease and can pave the way to potential therapy.

aDepartment of Nephrology, Rambam Healthcare Campus

bDepartment of Genetics and Developmental Biology, Rappaport Faculty of Medicine and Research Institute, Technion – Israel Institute of Technology, Haifa, Israel

Correspondence to Karl Skorecki, MD, Technion – Israel Institute of Technology, Haifa, Israel; Director of Medical and Research Development, Rambam Healthcare Campus, 8 Ha’Aliyah Street, Haifa 31096, Israel. Tel: +972 4 7773250; e-mail: skorecki@tx.technion.ac.il

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.